RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES AND CARDIAC BIOMARKERS: THE PREDICTION, RISK, AND EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS (PRE-MACE) STUDY BASELINE RESULTS

Abstract Aims Heart disease is recognized as the leading cause of morbidity and mortality in patients with muscular dystrophy (MD). Our study demonstrates the clinical utility of cardiac biomarkers to improve the diagnosis of cardiomyopathy and prognostication of major adverse cardiac events (MACE) in these vulnerable patients. Methods and results We prospectively followed 117 patients [median age, 42 [interquartile range (IQR), 26–50) years; 49 (41.9%) women] at the Neuromuscular Multidisciplinary clinic diagnosed with a dystrophinopathy, limb-girdle MD, type 1 myotonic dystrophy, or facioscapulohumeral MD. We determined that B-type natriuretic peptide (BNP) and high-sensitive troponin I (hsTnI) were effective diagnostic markers of cardiomyopathy [area under the curve (AUC), 0.64; P = 0.017; and AUC, 0.69; P = 0.001, respectively]. Patient risk stratification for MACE was based on cut-off values of BNP and hsTnI defined a priori as 30.5000 pg/mL and 7.6050 ng/L, respectively. Over a median follow-up period of 2.09 (IQR, 1.17–2.81) years there were 36 confirmed MACE. Multivariate regression analyses showed that patients with BNP and hsTnI levels above the respective cut-off values had a 3.70-fold (P = 0.001) and 3.24-fold (P = 0.002) greater risk of MACE, respectively, compared with patients with biomarker levels below. Furthermore, patients with biomarker levels above both cut-off values had a 4.08-fold (P = 0.001) greater risk of MACE. Inflammatory biomarkers did not show clinical utility for heart disease in these patients. Conclusion Our study demonstrates important diagnostic and prognostic value of BNP and hsTnI as part of a comprehensive cardiac assessment to augment the management and treatment of heart disease in patients with MD.

Download Full-text

Mo1937 Pretransplant Cardiac Biomarkers and Risk of Major Adverse Cardiac Events Following Liver Transplantation

Gastroenterology ◽

10.1016/s0016-5085(12)63890-6 ◽

2012 ◽

Vol 142 (5) ◽

pp. S-1004

Author(s):

Mazen Albeldawi ◽

Vedant Gupta ◽

Gurshawn Singh ◽

Paresh P. Mehta ◽

Rocio Lopez ◽

...

Keyword(s):

Liver Transplantation ◽

Major Adverse Cardiac Events ◽

Cardiac Biomarkers ◽

Cardiac Events ◽

Adverse Cardiac Events

Download Full-text

Feasibility of Patient-Centric Remote Dried Blood Sampling: The Prediction, Risk, and Evaluation of Major Adverse Cardiac Events (PRE-MACE) Study

Biodemography and Social Biology ◽

10.1080/19485565.2020.1765735 ◽

2019 ◽

Vol 65 (4) ◽

pp. 313-322

Author(s):

Garth Fuller ◽

Kelly Njune Mouapi ◽

Sandy Joung ◽

Chrisandra Shufelt ◽

Irene van den Broek ◽

...

Keyword(s):

Blood Sampling ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Adverse Cardiac Events ◽

Prediction Risk ◽

Patient Centric

Download Full-text

Faculty Opinions recommendation of Association between adherence to fractional flow reserve treatment thresholds and major adverse cardiac events in patients with coronary artery disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739032794.793581359 ◽

2020 ◽

Author(s):

Jerome Fleg

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Fractional Flow Reserve ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Fractional Flow ◽

Flow Reserve ◽

Adverse Cardiac Events ◽

Treatment Thresholds ◽

Artery Disease

Download Full-text

Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2021.03.005 ◽

2021 ◽

Author(s):

Katelyn M. Atkins ◽

Danielle S. Bitterman ◽

Tafadzwa L. Chaunzwa ◽

David E. Kozono ◽

Elizabeth H. Baldini ◽

...

Keyword(s):

Lung Cancer ◽

Radiation Therapy ◽

Coronary Artery ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Heart Dose ◽

Adverse Cardiac Events ◽

Mean Heart Dose

Download Full-text

Prognostic Value of Systemic Immune-Inflammation Index for Major Adverse Cardiac Events and Mortality in Severe Aortic Stenosis Patients after TAVI

Medicina ◽

10.3390/medicina57060588 ◽

2021 ◽

Vol 57 (6) ◽

pp. 588

Author(s):

Aydin Rodi Tosu ◽

Muhsin Kalyoncuoglu ◽

Halil İbrahim Biter ◽

Sinem Cakal ◽

Murat Selcuk ◽

...

Keyword(s):

Aortic Stenosis ◽

Prognostic Value ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Short Term ◽

Cox Regression Analysis ◽

Adverse Cardiac Events ◽

All Cause Mortality ◽

Auc Value ◽

Immune Inflammation

Background and objectives: In this study, we aimed to evaluate whether the systemic immune-inflammation index (SII) has a prognostic value for major adverse cardiac events (MACEs), including stroke, re-hospitalization, and short-term all-cause mortality at 6 months, in aortic stenosis (AS) patients who underwent transcatheter aortic valve implantation (TAVI). Materials and Methods: A total of 120 patients who underwent TAVI due to severe AS were retrospectively included in our study. The main outcome of the study was MACEs and short-term all-cause mortality at 6 months. Results: The SII was found to be higher in TAVI patients who developed MACEs than in those who did not develop them. Multivariate Cox regression analysis revealed that the SII (HR: 1.002, 95%CI: 1.001–1.003, p < 0.01) was an independent predictor of MACEs in AS patients after TAVI. The optimal value of the SII for MACEs in AS patients following TAVI was >1.056 with 94% sensitivity and 96% specificity (AUC (the area under the curve): 0.960, p < 0.01). We noted that the AUC value of SII in predicting MACEs was significantly higher than the AUC value of the C-reactive protein (AUC: 0.960 vs. AUC: 0.714, respectively). Conclusions: This is the first study to show that high pre-procedural SII may have a predictive value for MACEs and short-term mortality in AS patients undergoing TAVI.

Download Full-text